Jounce Therapeutics, Inc. (JNCE)
Stock Price:
$9.55 USD
-0.29 (-2.95%)
Updated Oct 22, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
326.75M |
| Revenue (ttm) |
119.45M |
| Net Income (ttm) |
21.78M |
| Shares Out |
34.21M |
| EPS (ttm) |
0.63 |
| PE Ratio |
15.16 |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 22, 2020 |
| Last Price |
$9.55 |
| Previous Close |
$9.84 |
| Change ($) |
-0.29 |
| Change (%) |
-2.95% |
| Day's Open |
9.83 |
| Day's Range |
9.47 - 9.89 |
| Day's Volume |
305,531 |
| 52-Week Range |
2.85 - 11.72 |
More Stats
| Market Cap |
326.75M |
| Enterprise Value |
217.92M |
| Earnings Date (est) |
Nov 17, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
34.21M |
| Float |
16.59M |
| EPS (basic) |
0.70 |
| EPS (diluted) |
0.63 |
| FCF / Share |
-0.91 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
6.60% |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.59M |
| Short Ratio |
0.51 |
| Short % of Float |
9.56% |
| Beta |
1.69 |
| PE Ratio |
15.16 |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
2.74 |
| PB Ratio |
2.67 |
| Revenue |
119.45M |
| Operating Income |
18.88M |
| Net Income |
21.78M |
| Free Cash Flow |
-31.10M |
| Net Cash |
108.83M |
| Net Cash / Share |
3.18 |
| Gross Margin |
102.14% |
| Operating Margin |
15.81% |
| Profit Margin |
18.20% |
| FCF Margin |
-26.04% |
| ROA |
6.75% |
| ROE |
20.05% |
| ROIC |
16.80% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (7)
| Buy |
3 |
| Overweight |
1 |
| Hold |
2 |
| Underweight |
0 |
| Sell |
1 |
Analyst Consensus: Overweight
Price Target
$14.30*
(49.74% upside)
Low
5.50
Current: $9.55
High
28.00
Target: 14.30
*Average 12-month price target from 5 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|
| Revenue | 148 | 65.20 | 71.64 | 37.20 | - | - |
| Revenue Growth | 126.79% | -8.99% | 92.61% | - | - | - |
| Gross Profit | 148 | 65.20 | 71.64 | 37.20 | - | - |
| Operating Income | 52.82 | -31.29 | -19.22 | -14.47 | -30.40 | -16.21 |
| Net Income | 56.82 | -27.38 | -16.44 | -13.70 | -28.53 | -10.52 |
| Shares Outstanding | 33.08 | 32.57 | 30.06 | 2.10 | 1.62 | 1.18 |
| Earnings Per Share | 1.66 | -0.84 | -0.57 | -11.00 | -23.13 | -10.93 |
| Operating Cash Flow | -30.13 | -63.61 | -90.99 | 180 | -25.74 | -14.91 |
| Capital Expenditures | -0.99 | -1.36 | -15.11 | -2.22 | -2.20 | -0.70 |
| Free Cash Flow | -31.11 | -64.97 | -106 | 177 | -27.94 | -15.61 |
| Cash & Equivalents | 169 | 190 | 236 | 149 | 45.16 | 45.16 |
| Total Debt | 19.79 | - | - | - | - | - |
| Net Cash / Debt | 149 | 190 | 236 | 149 | 45.16 | 45.16 |
| Assets | 206 | 214 | 297 | 271 | 52.98 | 52.98 |
| Liabilities | 31.29 | 110 | 130 | 199 | 8.12 | 8.12 |
| Book Value | 175 | 104 | 167 | -69.09 | -58.76 | -58.76 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Jounce Therapeutics, Inc. |
| Country |
United States |
| Employees |
130 |
| CEO |
Richard Murray |
Stock Information
| Ticker Symbol |
JNCE |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: JNCE |
| IPO Date |
January 27, 2017 |
Description
Jounce Therapeutics, a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company offers vopratelimab, a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors, which is in Phase II clinical trial for the treatment of PD-1/PD-L1 inhibitor patients with non-small cell lung cancer and urothelial cancer. It is also developing JTX-4014, a clinical-stage anti-PD-1 antibody for combination therapy; and JTX-1811, a monoclonal antibody designed to selectively deplete T regulatory cells in the tumor microenvironment that is in the IND-enabling phase. The company's product candidate includes JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.